Nuclear Medicine Market Analysis

Imaging Segment Analysis 

The PET imaging segment is estimated to account for the largest share of 41% in the market over the discussed timeframe. PET imaging is projected to have the largest revenue share within the Imaging segment by 2035, due to effective diagnostic performance. In particular, PET scans have been found effective at an early stage in diagnosing cancers, cardiovascular diseases, and neurological disorders. PET imaging's performance is superior, as it demonstrates both tissue structure as well as metabolic function for high precision diagnosis and disease outcome. In addition, PET imaging plays an integral role in cancer staging, which is essential in treatment design and treatment outcomes.

Therapeutics Segment Analysis  

The radioligand therapy segment is poised to dominate the market with a share of 33% during the analyzed period. Radioligand therapy (RLT) utilizes targeted radiopharmaceuticals to deliver radiation directly to cancer cells, sparing healthy tissue. The growing efficacy of RLT in treating both prostate cancer and neuroendocrine tumors accelerated the market growth. RLT can also treat cancer, where conventional therapies have limited options.

Therapeutic Radiopharmaceuticals Segment Analysis  

During the examined period, the radioactive iodine segment is expected to hold a 37% market share in the nuclear medicine industry. Radioactive iodine has been used to treat thyroid cancer and hyperthyroidism for decades. Its success as the most utilized radiopharmaceutical in the Therapeutic Radiopharmaceuticals segment will continue as the incidence of thyroid conditions increases across the globe. It is effective because it targets thyroid tissue and is a very effective and minimally invasive therapy. Recent advances in dosimetry and proper patient selection have resulted in greater success.

Our in-depth analysis of the global market includes the following segments: